NVO Jun 2024 125.000 call
| Previous close | 5.3500 |
| Open | 5.3500 |
| Bid | 4.4000 |
| Ask | 4.5500 |
| Strike | 125.00 |
| Expiry date | 2024-06-21 |
| Day's range | 4.0000 - 5.3500 |
| Contract range | N/A |
| Volume | |
| Open interest | 2.09k |
- Yahoo Finance Video
Weight-loss drug competition heats up. Is Wegovy in trouble?
The competition among weight-loss drugs is heating up as Amgen (AMGN) reports positive early results from the development of its GLP-1 weight-loss drug, MariTide. The pharmaceutical company also topped first-quarter revenue estimates despite reporting a loss of $113 million. Yahoo Finance Senior Health Reporter Anjalee Khemlani breaks down how competition in the obesity drug market is ramping up as drug manufacturers find new medical use cases for this class of drugs. She refers back to comments made by Novo Nordisk (NVO) CEO Lars Fruergaard Jørgensen — Novo Nordisk makes Wegovy and Ozempic — and Eli Lilly (LLY) CEO Dave Ricks — Eli Lilly makes Zepbound and Mounjaro — to Yahoo Finance over the past several months. For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Melanie Riehl
ReutersUS FTC seeks more information on Novo Nordisk parent-Catalent deal
Catalent said on Friday the companies were in the process of gathering information to respond to the U.S. Federal Trade Commission's request received on May 2. Novo Holdings in February agreed to buy Catalent to boost output of the popular weight-loss drug Wegovy.
- Reuters
UPDATE 2-US FTC seeks more information on Novo Nordisk parent-Catalent deal
The U.S. FTC has sought more information on Novo Nordisk parent's $16.5 billion bid for contract drug manufacturer Catalent, weeks after an application to the regulator was refiled for approval of the deal. Catalent said on Friday the companies were in the process of gathering information to respond to the U.S. Federal Trade Commission's request received on May 2. Novo Holdings in February agreed to buy Catalent to boost output of the popular weight-loss drug Wegovy.
